Oncology Central

Mechanisms of resistance to EGFR inhibitors in colorectal cancers


The EGF receptor (EGFR) is important in the regulation of proliferation, apoptosis and angiogenesis in cancer. EGFR inhibitors have become a mainstay of treatment of metastatic colorectal cancer, in particular KRAS wild-type patients in 50–60% of patients. Despite this many patients do not respond to these agents.

To view restricted content, please:

Leave A Comment